Doxorubicin Dose Escalation, with or without Taxol®, as Part of the CA Adjuvant Chemotherapy Regimen for Node Positive Breast Cancer: A Phase III Intergroup Study

p53 expression in node-positive breast cancer patients: results from the cancer and leukemia group B 9344 trial (159905) [PMID21693655; PMC3149770]

JF Lara;LG Dressler;G Broadwater;IJ Bleiweiss;S Edgerton;D Cowan;L Goldstein;S Martino;J Ingle;IC Henderson;L Norton;E Winer;C Hudis;MJ Ellis;DA Berry;DF Hayes Clinical Cancer Research 17(15):5170-5178

HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344.

DF Hayes;A Thor;L Dressler;D Weaver;G Broadwater;L Goldstein;S Martino;J Ingle;IC Henderson;D Berry Proc of the ASCO, Journal of Clinical Oncology 24(18S):#510

Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer

IC Henderson;DA Berry;GD Demetri;CT Cirrincione;L Goldstein;S Martino;JN Ingle;MR Cooper;DF Hayes;KH Tkaczuk;G Fleming;JF Holland;DB Duggan;JT Carpenter;E Frei, III;RL Schilsky;WC Wood;HB Muss;L Norton Journal of Clinical Oncology 21(6):976-983

Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC).

IC Henderson;D Berry;G Demetri;C Cirrincione;L Goldstein;S Martino;JN Ingle;MR Cooper;G Canellos;E Borden;G Fleming;JF Holland;S Graziano;J Carpenter;H Muss;L Norton Proc of the American Society of Clinical Oncology 17:101a(#390a)